Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

INTELLIA THERAPEUTICS, INC. (NTLA) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

INTELLIA THERAPEUTICS, INC. (NTLA), most recent 12 months reported: revenue $59.51M, net loss $399.98M, free cash flow -$348.69M. Latest balance sheet on file: liquid cash $437.76M. From SEC filings. Others in In Vitro & In Vivo Diagnostic Substances: QUIDELORTHO CORP · Lantheus Holdings, Inc. · Neogen Corporation · MYRIAD GENETICS, INC. · Alpha Teknova, Inc. · ImmuCell Corporation · Anbio Biotechnology · Aspira Women’s Health Inc.

Stock screener

Watchlist